🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Impact of Epigenetic Age on Clinic-biological Presentation and Prognosis in Myeloproliferative Neoplasms Epigenetic Age in Myeloproliferative Neoplasms (EpiC)

Recruitingn/aAges 18 Years - anyAllUniversity Hospital, Bordeaux
NCT06022328 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Myeloproliferative Neoplasms (MPN) are hematological malignancies characterized by the excessive production of myeloid cells. MPN can be complicated by thrombosis and evolution into more aggressive diseases (myelofibrosis and acute leukemia). Aging remains the principal factor determining patients' survival in MPN. In recent years, DNA methylation has appeared as a mean to measure aging via the development of epigenetic clocks that have also been associated with the occurrence of thrombosis and cancer. The epiC project aims at determining epigenetic age of MPN patients and search for an association between this parameter and thrombotic/hematological complications.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: For the 110 patients with MPN: * Patients with PV, ET or PMF * DNA extracted from purified granulocytes at time of diagnosis * No treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) For the 10 subjects without MPN: * Absence of hematological malignancy * Search for JAK2V617F mutation in the context of reactive thrombocytosis or secondary polycythemia * Absence of treatment likely to impact DNA methylation (chemotherapy, immunosuppressants in particular) Exclusion Criteria: For the 110 patients with MPN: * Patients without PV, ET or PMF * Patients without purified granulocytes DNA available at time of diagnosis * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling * Patients with less than 2 years' follow-up For the 10 subjects in NMP : * Patients with hematological malignancy and/or solid cancer * Patients treated by cytoreductive drug, demethylating agent, chemotherapy or immunosuppressive therapy at the time of DNA sampling
💊

What it tests

  • Assessment of the epigenetic age
📍

Where

1 site
CHU de Bordeaux, service Hématologie Biologique
Bordeaux, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy